51
|
Abstract
An increased understanding of the biology of lung cancer has identified biological targets for rationally designed novel therapies. Most of these targets are components of signalling pathways or metabolic processes. EGFR-tyrosinkinase inhibitors have become standard in second- and thirdline therapy of NSCLC, the anti-VEGF-antibody Avastin combined with first-line chemotherapy showed a significant survival benefit over chemotherapy alone. There are ongoing studies with targeted therapies in all stages of lung cancer. Major advances of these new drugs are their low toxicity and, in part, the oral application.
Collapse
|
52
|
Abstract
Despite medical advances lung cancer remains the leading cause of cancer deaths. Lung cancer is usually recognized late in its natural history and at presentation in 80 % unresectable. Smoking history is the most important risk factor. At present time, screening for lung cancer is not recommended. The only chance for cure is tumour resection in early stages, performed in about 20 % of all lung cancer cases. Histological subtypes are non-small cell lung cancer (NSCLC) (80 % of lung cancers) and 20 % small cell lung cancer (SCLC). TNM-staging has important influence on prognosis and therapy. After identification the tumour should be staged using the TNM system. Currently diagnosis and staging rely predominantly on chest radiography and computed tomography (CT) scanning. Positron emission tomography (PET) identifies the tumour by its metabolic activity and helps to find malignant nodal or systemic lesions. Flexible bronchoscopy is the key investigation in the diagnosis and staging of patients with suspected lung cancer. Endobronchial ultrasound guided transbronchial fine needle aspiration (TBNA) may be utilized to improve the bronchoscopic results in mediastinal staging. Internistic thoracoscopy or video assisted thoracoscopic surgery (VATS) may be used in malignant pleural effusions. Mediastinoscopy staging is the gold-standard for mediastinal staging.
Collapse
MESH Headings
- Biopsy, Fine-Needle
- Bone and Bones/diagnostic imaging
- Bronchoscopy/methods
- Carcinoma, Non-Small-Cell Lung/diagnosis
- Carcinoma, Non-Small-Cell Lung/pathology
- Carcinoma, Non-Small-Cell Lung/surgery
- Carcinoma, Non-Small-Cell Lung/therapy
- Carcinoma, Small Cell/diagnosis
- Carcinoma, Small Cell/pathology
- Carcinoma, Small Cell/surgery
- Carcinoma, Small Cell/therapy
- Humans
- Lung Neoplasms/diagnosis
- Lung Neoplasms/pathology
- Lung Neoplasms/surgery
- Lung Neoplasms/therapy
- Neoplasm Staging
- Paraneoplastic Syndromes/diagnosis
- Paraneoplastic Syndromes/pathology
- Paraneoplastic Syndromes/therapy
- Pleural Effusion, Malignant/diagnosis
- Pleural Effusion, Malignant/pathology
- Pleural Effusion, Malignant/surgery
- Pleural Effusion, Malignant/therapy
- Prognosis
- Radiography, Thoracic
- Risk Factors
- Smoking/adverse effects
- Thoracoscopy
- Tomography, Emission-Computed/methods
- Tomography, X-Ray Computed/methods
Collapse
|
53
|
Serke M. [Pharmacologic treatment of bronchial cancer. Part 1: Standards]. Pneumologie 2006; 60:493-508. [PMID: 16933193 DOI: 10.1055/s-2006-944265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
In the last decade there have been important innovations in the treatment of lung tumors. New combined modality therapies are becoming standard and require a network of cooperating partners. New therapeutic agents are under investigation that will hopefully improve the outcome of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). Principles of chemotherapy in non-small cell und small cell lung cancer depending on stage and combination in multimodal regimens are shown. In the second part single drugs are described with their typical effects and side effects from the viewpoint of a clinician. A following part II will discuss new "targeted" biologicals.
Collapse
|
54
|
Serke M, Kaiser D, Fisseler-Eckhoff A, Mairinger T, Loddenkemper R. P-426 Multimodal therapy in 328 patients with malignant pleuralmesothelioma. Lung Cancer 2005. [DOI: 10.1016/s0169-5002(05)80919-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
55
|
Serke M, Loddenkemper R. [Therapeutic options in malignant pleural mesothelioma]. Pneumologie 2005; 59:337-48. [PMID: 15902599 DOI: 10.1055/s-2004-830287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Malignant pleural mesothelioma may be treated with surgery, radiotherapy and chemotherapy. In most patients, the treatment remains palliative with symptom relief and a moderate survival gain. Only a minority of patients with early stage mesothelioma may be cured by a multimodal approach including radical surgery, chemotherapy, and radiotherapy. We discuss the role of surgery with either radical extrapleural pleuropneumonectomy or less invasive palliative pleurectomy and decortication, and the role of radiotherapy, in which the main problem is how to deliver sufficient doses to the pleural surface, sparing radiosensitive structures such as the lung, heart, liver, and kidneys. Chemotherapeutic options are discussed with 'older' mono- and combination regimens and the new promising combination cisplatinum/pemetrexed, now the 'standard regimen' for malignant pleural mesothelioma. Experimental approaches such as hyperthermia, interferons or interleukins, and 'small molecules' or antibodies inhibiting the EGFR oder VEGF receptor are under clinical evaluation. For the majority of our patients we recommend talcum pleurodesis either by medical thoracoscopy or VATS, followed by chemotherapy with platinum/pemetrexed. Radiotherapy may be applied in case of local tumour growth. The individual therapeutic decision will depend on tumour stage, concomitant diseases, performance status, and on the patient's preference.
Collapse
|
56
|
Serke M, Dittrich I, Bohnenstengel A, Loddenkemper R. Erfahrungen mit der Therapie mit ZD 1839 (IRESSA) im Rahmen eines „expanded acces-Programmes“ (EAP) an Patienten mit ausbehandeltem NSCLC. Pneumologie 2005. [DOI: 10.1055/s-2005-864561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
57
|
Schwarz C, Lübbert H, Rahn W, Schönfeld N, Serke M, Loddenkemper R. Medical thoracoscopy: hormone receptor content in pleural metastases due to breast cancer. Eur Respir J 2004; 24:728-30. [PMID: 15516663 DOI: 10.1183/09031936.04.00069104] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Pleural metastases are common in the course of breast cancer, but, to date, the role of oestrogen receptor (OR) and progesterone receptor (PgR) content in metastatic tissue has been poorly evaluated. A series of 50 consecutive patients with a history of breast cancer (median age 64 yrs, range 40-86 yrs), which presented with pleural effusion and therefore underwent medical thoracoscopy, was analysed. Metastatic pleural involvement was histologically confirmed in all patients. The hormone receptor status of the pleural metastases was investigated using the immunohistochemical method in 49 and the biochemical method in 31 cases. The immunohistochemical test was performed using monoclonal antibodies. Biochemical analysis was performed on specimens quick-frozen in liquid nitrogen. OR and PgR were measured with the dextran-coated charcoal assay and Scatchard analysis. Immunohistochemical analysis yielded 29 OR-positive and 25 PgR-positive cases and biochemical analysis yielded 16 OR-positive and four PgR-positive cases, sometimes discrepant to hormone status of the primary breast cancer. Using a semiquantitative immunoreactive score, there was a significant association between receptor positivity and survival, but only for PgR positivity. Immunohistochemical and biochemical detection of hormone receptors (oestrogen and progesterone) in pleural metastases of breast cancer is feasible based on medical thoracoscopy as the method of choice, by which sufficient specimens may be obtained. The receptor status may enable a decision on antihormonal treatment. Whether a positive receptor status in pleural metastatic tissue is associated with a better prognosis remains to be confirmed.
Collapse
|
58
|
Schuette W, Nagel S, Serke M, Lautenschlaeger C, Hans K, Lorenz C. Second-line chemotherapy for advanced non-small cell lung cancer (NSCLC) with weekly versus three-weekly docetaxel: Results of a randomized phase III study. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.7036] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
59
|
Serke M. [Adjuvant chemotherapy in non-small-cell lung cancer: proven survival benefit]. Pneumologie 2004; 58:393-4. [PMID: 15216430 DOI: 10.1055/s-2004-818500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
60
|
Eggeling S, Kaiser D, Allica E, Serke M. Ergebnisse der multimodalen Therapie des kleinzelligen Bronchialkarzinoms. Pneumologie 2004. [DOI: 10.1055/s-2004-819736] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
61
|
Kuhnke A, Serke M, Erbes R, Lode H. Ertapenembehandlung der chemotherapieinduzierten fieberhaften Neutropenie von Patienten mit Bronchialkarzinom. Pneumologie 2004. [DOI: 10.1055/s-2004-819711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
62
|
Serke M, Abay A, Kaiser D, Loddenkemper R. Adjuvante Chemo-Strahlentherapie vs. alleiniger Bestrahlung beim N2-NSCLC. Pneumologie 2004. [DOI: 10.1055/s-2004-819731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
63
|
Schütte W, Nagel S, Serke M, Lautenschläger C. Randomisierte Phase-III-Studie mit Docetaxel wöchentlich versus dreiwöchentlich in der Second-line-Behandlung des NSCLC. Pneumologie 2004. [DOI: 10.1055/s-2004-819735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
64
|
Allica E, Serke M, Loddenkemper R, Kaiser D. [Multimodality therapy concept in stage I-IIIA small cell bronchial carcinoma. Case follow-up over 15 years]. KONGRESSBAND. DEUTSCHE GESELLSCHAFT FUR CHIRURGIE. KONGRESS 2002; 118:596-600. [PMID: 11824323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
We analysed our results of multimodal therapy including chemotherapy, radiotherapy and surgery in 150 consecutive patients with SCLC stage I-IIIa operated on in our hospital between 1983 and 2000. Median age: 58 years, stages see Table 2. Patients with proven SCLC had induction chemotherapy prior to surgery. All patients received three cycles of adjuvant chemotherapy, some with additional radiotherapy. Perioperative mortality: 2%. Median survival: 22.4 months. R0 resection was possible in 84% of all patients. Pre- and post-surgery staging differed in the majority of the patients. Rotes of 1-, 2- and 5-year survival were 79%, 47%, and 32%, respectively. A median survival of 22.4 months in multimodally treated LD-SCLC, most of them stage IIb/IIIa appears promising. Randomized studies based on clinical staging procedures are not recommended. Survival data are promising.
Collapse
|
65
|
Serke M, Allica E, Wolf M, Schönfeld N, Kaiser D, Loddenkemper R. [Non-small-cell bronchial carcinoma with pathological N2 involvement: adjuvant radiotherapy versus adjuvant chemo-radiotherapy]. KONGRESSBAND. DEUTSCHE GESELLSCHAFT FUR CHIRURGIE. KONGRESS 2002; 118:606-10. [PMID: 11824325] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Fifty-eight patients, 28 of them included in a German multicenter study, were treated either with radiotherapy (5 x 2 Gy/50 Gy) or combined radio-chemotherapy (cisplatin 75 mg/m2 d1 in cases with pneumonectomy etoposide 120 mg/m2 d1-3) and Ifosfamid 1.5 mg/m2 d1-4, 3 cycles) following surgery in pN2-NSCLC. Metastatic disease or local failure was seen in 24 patients (43%), in the majority with distant metastasis (n = 21), in 4 patients combined local and distant failure. Time to progression (TTP) was 27 to 1172 days, median 244 days. Median survival of the whole group was 873 days (= 29 months), the 3-year survival 49%. Comparing the two groups there was an advantage (not significant) in favor of the combined treated group with a median survival of 1449 days versus 765 days (p = 0.22).
Collapse
|
66
|
Thomas M, Baumann M, Deppermann M, Freitag L, Gatzemeier U, Huber R, Passlick B, Serke M, Ukena D. [Recommendations on the therapy of bronchial carcinoma]. Pneumologie 2002; 56:113-31. [PMID: 11842350 DOI: 10.1055/s-2002-20093] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
67
|
Serke M, Argiropolus D, Schönfeld N, Loddenkemper R. Weekly docetaxel as second line chemotherapy in advanced non small cell lung cancer (NSCLC): Final results and survival analysis. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80679-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
68
|
Abstract
Previous studies suggested that the characteristics of young female lung cancer patients may differ from those of other patients. Using the cancer registry at the Lungenklinik Heckeshorn hospital, all female patients under the age of 46 yrs with primary lung cancer 1986-1995 were identified. The clinical records were reviewed for risk factors, stage, histology, therapy, and survival. The data were compared with those of other patients. Of the 4,939 patients 96 (1.9%) were females aged <46 yrs. The percentage of young females doubled within ten years from 1 to 2% of all patients (p=0.03). The main risk factor in young females was smoking. Adenocarcinoma and carcinoids were overrepresented, whereas squamous cell and small cell carcinoma were significantly rarer in the young female group. Young females and young males were more likely to have advanced disease and underwent surgery and/or combined treatment significantly more often than older patients. The overall survival was only moderately better in younger patients. The clinical features of young female patients differed from those of young males and older females, the prognosis likewise depended on tumour stage and therapy.
Collapse
|
69
|
Serke M, Rücker M, Riedel U, Schoenfeld N, Loddenkemper R. Chemotherapy in advanced NSCLC: Randomized comparison of ifosfamid/vindesin (IFO/VDS) versus mitomycin/ifosfamid/cisplatin (MIC). Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80069-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
70
|
Serke M, Rücker M, Schönfeld N, Loddenkemper R. Second line weekly docetaxel in advanced non small cell lung cancer. Lung Cancer 2000. [DOI: 10.1016/s0169-5002(00)80240-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
71
|
Serke M. [Established new drugs in the chemotherapy of non-small-cell lung carcinoma (NSCLC)]. Dtsch Med Wochenschr 2000; 125:225. [PMID: 10723459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/15/2023]
|
72
|
Schönfeld N, Temme T, Serke M, Loddenkemper R. [High frequency diathermy--a new method in the treatment of malignant and benign stenosis of the airways]. Pneumologie 1999; 53:477-9. [PMID: 10596549 DOI: 10.1055/s-1999-9043] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
High-frequency electrocautery is a relatively new method in the treatment of malignant or benign airway stenoses. We report on the results of 58 sessions in 41 patients (malignant condition n = 30, benign n = 11) within a three-year period. Various instruments were available for coagulation (blunt probe, knives of 4, 5 and 7 mm length, forceps and wire snare). 53/58 sessions were performed under general anaesthesia, energy was limited to 40 W with unlimited duration of pulses. The knives were the most frequently used devices, preferably with a length of 5 mm, which enabled us to either cut the tumour or scar tissue precisely slice by slice or to resect by direct coagulation. The use of the blunt probes and forceps was frequently rendered more difficult by detritus covering the instrument during coagulation. Polypes were easily resected with the wire snare, but this kind of tumour was found in four patients only. Major (> 100 ml) bleeding occurred in two patients. Obstructing fibrinous membranes were never seen after electrocautery. In conclusion, high-frequency electrocautery is an effective and safe method for endobronchial resection and can be considered a good alternative to the laser as the classical method for endobronchial resection.
Collapse
|
73
|
Schönfeld N, Lienert T, Serke M, Kaiser D, Loddenkemper R. [Bronchial carcinoma in young adults]. Pneumologie 1999; 53:480-4. [PMID: 10596550 DOI: 10.1055/s-1999-9041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Lung cancer in young adults has been differently described in publications from various regions of the world, in respect of relative incidence, distribution of morphology and stages, and prognosis of the disease. We analysed retrospectively the data from the cancer registry of the Lungenklinik Heckeshorn in Berlin between 1986 and 1995 with regard to this topic. 106/4939 patients were 40 years old or younger (2.1%). The proportion of female patients was higher in the younger group (42 vs. 29%). Adenocarcinoma was the leading subtype in young patients (33 vs. 24%). The younger group showed a higher proportion of inoperable stages IIIB and IV for non-small cell lung cancer (71 vs. 46%). Younger patients with operable stages I to IIIA non-small cell lung cancer underwent surgery much more often than patients older than 40 years (90 vs. 49%), but for all patients with this morphology there was no difference in survival between younger and older patients (302 vs. 314 patients). We conclude that lung cancer presents a clearly different clinical picture in younger patients but not a better prognosis.
Collapse
|
74
|
Serke M, Riedel U, Schönfeld N, Pannhorst J, Förster B, Loddenkemper R. [Combined alternating radiochemotherapy in stage III (TNM) (limited disease) small cell bronchial carcinoma: a phase II study with carboplatin/etoposide/vincristine and alternating radiotherapy]. Pneumologie 1999; 53:485-92. [PMID: 10596551 DOI: 10.1055/s-1999-9042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
BACKGROUND The combination of radio-chemotherapy is accepted standard in limited-disease small cell lung cancer, but the best way of combining the two modalities is still unknown. To test an alternating regime of early radiotherapy with hypofractionated radiotherapy we performed a phase II study in stage III small cell lung cancer. METHOD 32 SCLC patients (n = 7 IIIa, n = 25 IIIb) were treated with a weekly alternating regime with either chemotherapy or radiotherapy. Chemotherapy included carboplatin (AUC5), etoposide (3 x 120 mg/m2) and vincristine (2 mg), repeated on day 28 for six cycles. Radiotherapy started one week before chemotherapy and was applied weekly 1 x 4 Gy, using a split-course regimen. RESULTS Combined radio-chemotherapy was well tolerated with dose-limiting hemotoxicity and very few cases of oesophagitis. Overall response was 75%, median survival 14.5 months and the 2-year survival was 34.4%. 5 patients are still living now for more than 29 months. Treatment failure was local and systemic in 34% of the patients. Systemic failure included 6 patients with brain metastases. CONCLUSION Combined radio-therapy in small-cell lung cancer using an alternating hypofractionated regimen is well tolerated. Response rate and 2-year survival are promising. Local and systemic failure is an ongoing problem and requires better local and systemic control of the disease.
Collapse
|
75
|
Guschall WR, Dittrich I, Gatzemeier U, Serke M, Riedel U, Mehl B, Baumgart J, Drings P. Clinical phase II trial of intravenous treosulfan in patients with non-pretreated metastatic small-cell lung cancer. Lung Cancer 1999. [DOI: 10.1016/s0169-5002(99)90799-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|